The PISA platform, developed by the Biology Laboratory run by Professor Cattaneo, will participate in the final competition of the “Intellectual Property Award 2021” announced by the Ministry of Economic Development.
The PISA biomedical patent, owned by the Scuola Normale Superiore, has been selected for the final competition of the " Intellectual Property Award 2021”, which will take place at the Dubai Expo. It will participate on Monday 28 February and Tuesday 1 March in the world showcase that from October 1 to March 31 sees 200 countries from all over the world present the best of their ideas, projects and innovative models in the field of tangible and intangible infrastructures.
PISA, acronym for Post-translational Intracellular Silencing Antibodies, was among the 5 best patents in the Life-Science/Health Care sector, one of the 7 macro disciplinary areas envisaged by "IPA 2021", a competition organized by the Ministry of Economic Development to allow Italian academic and research institutions to promote the best insights regarding technological innovation. In all, 216 patents participated in the event, 79 of them for the Life Science/Health Care area.
Gabriele Ugolini, R&D Business Development Director of P.I.S.A. Biotech (the entrepreneurial project which had already won the last edition of StartCup Toscana and was among the finalists of the National Innovation Award 2021) will present (at the Padiglione Italia) the PISA technology created by Antonino Cattaneo, Michele Chirichella and the Biology Laboratory of the Scuola Normale. PISA is a new technological platform that will be able to select specific antibodies for hitherto unattainable therapeutic targets: PTM proteins, which may be responsible for important pathologies, including neurodegenerative diseases such as Alzheimer's, as well as oncological diseases.
In total there are 35 finalist patents for the 7 disciplinary areas of “IPA2021”. A jury will select the winner for each area.